Clinical Trial Update: Evaluation of the Potential for Cytochrome P450 3A4 Inhibition by F901318 Using Oral Midazolam as a Probe [Phase 1]

View source ↗

Summary

Phase 1 trial completed to evaluate the potential of F901318 to inhibit CYP3A4 using oral midazolam as a probe. The study assesses drug–drug interaction risk fo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Invasive Aspergillosis

Drugs mentioned

• F901318
• Midazolam (Midazolam)

Snippet

Sponsor: F2G Biotech GmbH | Conditions: Invasive Aspergillosis | Phase 1 | Status: COMPLETED